- Home
- NKSH vs CNTX Comparison
NKSH vs CNTX Comparison
Compare NKSH & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- CNTX
- Stock Information
- Founded
- NKSH 1891
- CNTX 2015
- Country
- NKSH United States
- CNTX United States
- Employees
- NKSH N/A
- CNTX N/A
- Industry
- NKSH Major Banks
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- NKSH Finance
- CNTX Health Care
- Exchange
- NKSH Nasdaq
- CNTX Nasdaq
- Market Cap
- NKSH 182.9M
- CNTX 149.6M
- IPO Year
- NKSH N/A
- CNTX 2021
- Fundamental
- Price
- NKSH $31.79
- CNTX $1.84
- Analyst Decision
- NKSH
- CNTX Strong Buy
- Analyst Count
- NKSH 0
- CNTX 3
- Target Price
- NKSH N/A
- CNTX $6.83
- AVG Volume (30 Days)
- NKSH 10.8K
- CNTX 318.3K
- Earning Date
- NKSH 11-26-2024
- CNTX 11-06-2024
- Dividend Yield
- NKSH 4.75%
- CNTX N/A
- EPS Growth
- NKSH N/A
- CNTX N/A
- EPS
- NKSH 1.44
- CNTX N/A
- Revenue
- NKSH $43,450,000.00
- CNTX N/A
- Revenue This Year
- NKSH N/A
- CNTX N/A
- Revenue Next Year
- NKSH $14.93
- CNTX N/A
- P/E Ratio
- NKSH $22.00
- CNTX N/A
- Revenue Growth
- NKSH N/A
- CNTX N/A
- 52 Week Low
- NKSH $25.18
- CNTX $0.77
- 52 Week High
- NKSH $37.00
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- NKSH 59.21
- CNTX 37.02
- Support Level
- NKSH $30.31
- CNTX $1.90
- Resistance Level
- NKSH $32.39
- CNTX $2.32
- Average True Range (ATR)
- NKSH 0.98
- CNTX 0.14
- MACD
- NKSH 0.14
- CNTX -0.04
- Stochastic Oscillator
- NKSH 74.89
- CNTX 9.80
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.